問卷

TPIDB > Search Result

Search Result

篩選

List

54Cases

2025-04-01 - 2030-06-18

Phase III

Active
A phase III, randomized, open-label, commissioner-blinded, multicenter trial evaluating ribegostomig in combination with bevacizumab, with or without tremelimumab, as first-line treatment for patients with advanced hepatocellular carcinoma (ARTEMIDE-HCC01).
  • Condition/Disease

    Advanced hepatocellular carcinoma

  • Test Drug

    Atezolizumab Bevacizumab Rilvegostomig (AZD2936) Tremelimumab

Participate Sites
8Sites

Recruiting8Sites

2019-12-01 - 2030-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Not yet recruiting4Sites

Recruiting12Sites

2020-12-01 - 2025-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-06-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-09-01 - 2027-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2022-04-01 - 2026-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-03-01 - 2025-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-03-01 - 2027-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2018-10-30 - 2022-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2021-10-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites